Prognostic implication of ezrin expression in esophageal squamous cell carcinoma
Article first published online: 17 MAR 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 104, Issue 5, pages 538–543, 1 October 2011
How to Cite
Xie, J.-J., Xu, L.-Y., Wu, Z.-Y., Zhao, Q., Xu, X.-E., Wu, J.-Y., Huang, Q. and Li, E.-M. (2011), Prognostic implication of ezrin expression in esophageal squamous cell carcinoma. J. Surg. Oncol., 104: 538–543. doi: 10.1002/jso.21909
- Issue published online: 6 SEP 2011
- Article first published online: 17 MAR 2011
- Manuscript Accepted: 15 FEB 2011
- Manuscript Received: 27 JUL 2010
- National High Technology Research and Development Program of China. Grant Number: 2006AA02A403
- Natural Science Foundation of China-Guangdong Joint Fund. Grant Number: U0932001
- National Natural Science Foundation of China. Grant Numbers: 30772485, 31000347
- prognostic factor
Background and Objectives
Ezrin, a member of the ezrin–radixin–moesin family, was implicated in tumor progression, metastatic dissemination, and adverse outcomes in several cancer types, including esophageal squamous cell carcinoma (ESCC). The purpose of this study was to explore the clinical significance of ezrin expression in ESCC.
Ezrin expression was detected on tissue microarrays of ESCC samples in 307 cases using immunohistochemical staining. Survival analysis was assessed by the Kaplan–Meier analysis. Relative risk was evaluated by the multivariate Cox proportional hazards model.
The staining pattern of ezrin was heterogeneous and varied from negative/weakly to intense expression in a cytoplasmic distribution. Kaplan–Meier survival analysis showed that ezrin expression was related to poor overall survival of ESCC patients (P = 0.023). Further analysis revealed that ezrin expression was associated with the survival in the cases of stage III/IV (P = 0.002); but did not influence the survival in the patients of stage I/II. Multivariate Cox analysis demonstrated that ezrin was an independent factor in prognosis of ESCC (P = 0.011).
Ezrin might be a new molecular marker to predict the prognosis of ESCC patients. J. Surg. Oncol. 2011; 104:538–543. © 2011 Wiley-Liss, Inc.